Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

  • Technology appraisal guidance
  • TA284
  • Published: 
Download guidance (PDF)

9 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessments Centre:

  • Cooper K, Pickett K, Frampton GK et al. Bevacizumab in combination with carboplatin and paclitaxel for the first-line treatment of ovarian cancer. A single technology appraisal. October 2012

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Manufacturer/sponsor:

  • Roche Products (bevacizumab)

II. Professional/specialist and patient/carer groups:

  • Macmillan Cancer Support

  • Ovacome

  • Ovarian Cancer Action

  • Rarer Cancers Foundation

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Obstetricians and Gynaecologists

  • Royal College of Pathologists

  • Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO)

  • Target Ovarian Cancer

  • United Kingdom Clinical Pharmacy Association

III. Other consultees:

  • Department of Health

  • Outer North East London PCT Cluster

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Health Care Improvement Scotland

  • MRC Clinical Trials Unit

  • National Collaborating Centre for Cancer

  • National Institute for Health Research Health Technology Assessment Programme

  • Southampton Health Technology Assessments Centre

C. The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on bevacizumab by attending the Committee discussions and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Marcia Hall, Consultant in Medical Oncology, nominated by organisation representing NCRI/RCP/RCR/ACP/JCCO – clinical specialist

  • Dr Sarah Blagden, Clinical Senior Lecturer/Honorary Consultant in Medical Oncology, nominated by organisation representing Ovarian Cancer Action – clinical specialist

  • Ms Louise Bayne, CEO, nominated by organisation representing Ovacome – patient expert

  • Dr Sharon Tate, Public Affairs Manager, nominated by organisation representing Target Ovarian Cancer – patient expert

D. The following individuals were nominated as NHS Commissioning experts by the selected PCT Cluster located to this appraisal. They gave their expert/NHS commissioning personal view on bevacizumab by attending the Committee discussions and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Mrs Oge Chesa, Commissioning and Interface Pharmacist Advisor, NHS Waltham Forest, selected by Outer North East London PCT Cluster – NHS commissioning expert

  • Ms Rajinder Nijjar, Lead Cancer Pharmacist, North East London Cancer Network, selected by Outer North East London PCT Cluster – NHS commissioning expert

E. Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Roche Products